ARS Pharmaceuticals, Inc.
SPRY
$5.24
-$0.15-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 116.93M | 98.99M | 84.28M | 142.77M | 112.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.93M | 98.99M | 84.28M | 142.77M | 112.34M |
| Cost of Revenue | 48.71M | 40.18M | 33.60M | 27.90M | 21.49M |
| Gross Profit | 68.22M | 58.81M | 50.67M | 114.87M | 90.85M |
| SG&A Expenses | 284.49M | 261.22M | 230.12M | 205.66M | 150.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 333.19M | 301.40M | 263.73M | 233.56M | 171.68M |
| Operating Income | -216.27M | -202.42M | -179.45M | -90.79M | -59.34M |
| Income Before Tax | -215.51M | -198.06M | -171.38M | -79.75M | -47.73M |
| Income Tax Expenses | -80.00K | -80.00K | -80.00K | 288.00K | 288.00K |
| Earnings from Continuing Operations | -215.43 | -197.98 | -171.30 | -80.04 | -48.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -215.43M | -197.98M | -171.30M | -80.04M | -48.02M |
| EBIT | -216.27M | -202.42M | -179.45M | -90.79M | -59.34M |
| EBITDA | -214.65M | -200.93M | -178.08M | -89.81M | -58.73M |
| EPS Basic | -2.17 | -2.00 | -1.74 | -0.81 | -0.49 |
| Normalized Basic EPS | -1.33 | -1.22 | -1.06 | -0.47 | -0.27 |
| EPS Diluted | -2.18 | -2.00 | -1.74 | -0.90 | -0.58 |
| Normalized Diluted EPS | -1.33 | -1.22 | -1.06 | -0.53 | -0.33 |
| Average Basic Shares Outstanding | 396.44M | 395.49M | 394.26M | 392.63M | 390.85M |
| Average Diluted Shares Outstanding | 396.44M | 395.49M | 394.26M | 414.44M | 412.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |